TESEC Corporation (TYO:6337)

Singular Genomics Systems Cash Flow Statement

Financials in millions JPY. Fiscal year is April - March.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2025	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Net Income	-	674	2,141	2,456	2,065	-251
Depreciation & Amortization	-	117	67	65	52	46
Loss (Gain) From Sale of Assets	-	1	-1	56	-	-
Loss (Gain) From Sale of Investments	-	-116	-17	-29	-23	-58
Other Operating Activities	-	-548	-328	-620	-25	100
Change in Accounts Receivable	-	597	-488	922	-1,575	238
Change in Inventory	-	1,093	-100	-1,325	-695	478
Change in Accounts Payable	-	-169	-255	59	80	136
Change in Other Net Operating Assets	-	118	-148	-139	4	-147
Operating Cash Flow	-	1,767	871	1,445	-117	542
Operating Cash Flow Growth	-	102.87%	-39.72%	-	-	13.39%
Capital Expenditures	-	-54	-64	-64	-30	-35
Sale of Property, Plant & Equipment	-	-	2	-	-	-
Cash Acquisitions	-	-22	-	-	-	-
Sale (Purchase) of Intangibles	-	-292	-231	-82	-5	-1
Investment in Securities	-	-528	468	39	-793	123
Other Investing Activities	-	-4	-26	-10	3	-57
Investing Cash Flow	-	-900	149	-117	-825	30
Long-Term Debt Repaid	-	-12	-	-	-	-
Net Debt Issued (Repaid)	-	-12	-	-	-	-
Repurchase of Common Stock	-	-99	-140	-229	-	-
Dividends Paid	-	-382	-551	-446	-58	-112
Other Financing Activities	-	-2	-	-1	-	-
Financing Cash Flow	-	-495	-691	-676	-58	-112
Foreign Exchange Rate Adjustments	-	89	224	163	156	11
Miscellaneous Cash Flow Adjustments	-	-	1	-1	-1	1
Net Cash Flow	-	461	554	814	-845	472
Free Cash Flow	-	1,713	807	1,381	-147	507
Free Cash Flow Growth	-	112.27%	-41.56%	-	-	7.19%
Free Cash Flow Margin	-	29.07%	9.36%	15.79%	-1.96%	14.70%
Free Cash Flow Per Share	-	309.60	144.81	244.90	-26.03	89.77
Cash Interest Paid	-	1	-	-	-	-
Cash Income Tax Paid	-	544	328	619	24	-49
Levered Free Cash Flow	-	1,190	354.88	628.75	-654.88	628
Unlevered Free Cash Flow	-	1,191	354.88	628.75	-654.88	628

Updated Jan 28, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.